RxDoctor Payments Data

Hani Sami, MD

Internal Medicine · Sierra Madre, CANPI 1306891957

Payments from drug & device makers

$2,847in general payments, 2019–2025

Across 131 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$458
  • Johnson & Johnson$451
  • Novo Nordisk$344
  • Lilly USA, LLC$278
  • Pfizer$198
  • Novartis$178
  • plus $939 from 14 others

What the payments were for

  • Food & beverage$2,847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,847 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$102,215
Medicare patients
223
Services billed
1,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab61$105,701
OzempicSemaglutide63$104,121
EliquisApixaban47$60,746
XareltoRivaroxaban35$46,154
MounjaroTirzepatide32$34,414
MyrbetriqMirabegron66$32,500
Repatha SureclickEvolocumab21$31,036
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$21,420
VascepaIcosapent Ethyl49$20,039
JanumetSitagliptin Phos/Metformin Hcl21$15,356
Cyclosporine24$11,487
Icosapent Ethyl33$8,830
Breo ElliptaFluticasone/Vilanterol19$8,468
Atorvastatin Calcium570$6,521
Spiriva HandihalerTiotropium Bromide11$5,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$458$105,70161 claims
Novo NordiskOzempic$344$104,12163 claims
PfizerEliquis$198$60,74647 claims
Johnson & JohnsonXarelto$451$46,15435 claims
Lilly USA, LLCMounjaro$278$34,41432 claims
Astellas Pharma US IncMyrbetriq$85$32,50066 claims
GSKAnoro Ellipta, Breo Ellipta$153$29,88835 claims
MerckJanumet$14$15,35621 claims
AbbVieSynthroid$163$1,52719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sierra Madre

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →